Preoperative lanreotide treatment in acromegalic patients with macroadenomas increases short-term postoperative cure rates: a prospective, randomised trial.

Mao ZG, Zhu YH, Tang HL, Wang DY, Zhou J, He DS, Lan H, Luo BN, Wang HJ

European journal of endocrinology8 Jan 2010Cited by 76 (Europe PMC)

PMID20061334DOI10.1530/eje-09-0908PepBankPUB-20061334

Summary

The text of this summary is not shown here, because the article license does not allow reuse. Read it at the source (opens in a new tab)

Text rights: Publisher copyright. Results still quote short attributed sentences.

Results from this study3

3 results from studies that gave the peptide. 3 results from people.

01HumanRandomized controlled trialEfficacy outcome
At 4 months after surgery, cure was 49.0% with lanreotide pretreatment versus 18.4% with direct surgery in acromegaly with macroadenomas, P=0.001.
In plain wordsIn acromegaly with large pituitary tumors, lanreotide pretreatment increased cure at 4 months after surgery compared with direct surgery.
Peptide
Lanreotide
Outcome
IncreasePostoperative cure
Study
n = 98
Comparator
Direct transsphenoidal surgery
Analysis
Primary
Outcome group
Growth hormone and IGF-1 · Endocrine and hormones
Studied dose
30 mg every 2 weeks, increased to weekly at week 8 if mean GH >2.5 microg/l · intramuscular · 4 monthsAs given in this study (human).
Measurements
Cured
24 patients
lanreotide
Cure rate
49%
lanreotide
95% CI
35 to 63%
lanreotide
Cured
9 patients
direct surgery
Cure rate
18.4%
direct surgery
95% CI
7.6 to 29.2%
direct surgery
Source sentences
Summary
Cure was established in 24 of 49 (49.0%, 95% confidence interval (CI), 35.0-63.0%) pretreated patients (Group 1) versus 9 of 49 (18.4%, 95% CI, 7.6-29.2%) direct surgery patients (Group 2; P=0.001).
3 context sentences(design, population, supporting numbers)
Summary · context
After a baseline evaluation, patients were randomly assigned to 4-month preoperative treatment with lanreotide (starting with 30 mg/2 weeks i.m. and increasing to 30 mg/week i.m. at week 8 if mean GH >2.5 microg/l on GH day curves; pretreatment group, Group 1) or to transsphenoidal surgery (direct s…
Summary · context
Cure was evaluated 4 months postoperatively primarily by fasting IGF1 less than or equal to age-adjusted upper limit of normal.
Summary · context
Five patients in each group were lost to follow-up during the study period, so 49 patients in each group were analysed.
Report a problemFND-2006133401
02HumanRandomized controlled trialSafety outcome
In acromegaly with macroadenomas, surgical morbidity was similar after lanreotide pretreatment and direct surgery: 14.3% versus 10.2%, P=0.538.
In plain wordsIn acromegaly with large pituitary tumors, surgical complications were similar after lanreotide pretreatment and direct surgery.
Peptide
Lanreotide
Outcome
No significant changeSurgical morbidity
Study
n = 98
Comparator
Direct transsphenoidal surgery
Outcome group
Adverse events · Whole body
Studied dose
30 mg every 2 weeks, increased to weekly at week 8 if mean GH >2.5 microg/l · intramuscular · 4 monthsAs given in this study (human).
Measurements
Surgical morbidity
12 patients
both groups
Surgical morbidity
12.2%
both groups
Surgical morbidity
14.3%
lanreotide pretreatment
Surgical morbidity
10.2%
direct surgery
Source sentences
Summary
Surgical morbidity was recorded in 12 patients (12.2%) and was similar in Group 1 and 2 patients (14.3 and 10.2% respectively; P=0.538).
3 context sentences(design, population, supporting numbers)
Summary · context
After a baseline evaluation, patients were randomly assigned to 4-month preoperative treatment with lanreotide (starting with 30 mg/2 weeks i.m. and increasing to 30 mg/week i.m. at week 8 if mean GH >2.5 microg/l on GH day curves; pretreatment group, Group 1) or to transsphenoidal surgery (direct s…
Summary · context
Cure was evaluated 4 months postoperatively primarily by fasting IGF1 less than or equal to age-adjusted upper limit of normal.
Summary · context
Five patients in each group were lost to follow-up during the study period, so 49 patients in each group were analysed.
Report a problemFND-2006133402
03HumanRandomized controlled trialEfficacy outcome
In acromegaly with macroadenomas, hospital stay was similar after lanreotide pretreatment and direct surgery: 4.5+/-1.6 versus 4.8+/-1.9 days, P=0.328.
In plain wordsIn acromegaly with large pituitary tumors, hospital stays were similar after lanreotide pretreatment and direct surgery.
Peptide
Lanreotide
Outcome
No significant changePostoperative hospital stay
Study
n = 98
Comparator
Direct transsphenoidal surgery
Outcome group
Intensive care and hospital outcomes · Whole body
Studied dose
30 mg every 2 weeks, increased to weekly at week 8 if mean GH >2.5 microg/l · intramuscular · 4 monthsAs given in this study (human).
Measurements
Postoperative hospital stay, mean
4.5 days
lanreotide pretreatment, +/-1.6
Postoperative hospital stay, mean
4.8 days
direct surgery, +/-1.9
Source sentences
Summary
The postoperative hospital stay was similar between groups: being 4.5+/-1.6 days in Group 1 vs 4.8+/-1.9 days in Group 2 (P=0.328).
3 context sentences(design, population, supporting numbers)
Summary · context
After a baseline evaluation, patients were randomly assigned to 4-month preoperative treatment with lanreotide (starting with 30 mg/2 weeks i.m. and increasing to 30 mg/week i.m. at week 8 if mean GH >2.5 microg/l on GH day curves; pretreatment group, Group 1) or to transsphenoidal surgery (direct s…
Summary · context
Cure was evaluated 4 months postoperatively primarily by fasting IGF1 less than or equal to age-adjusted upper limit of normal.
Summary · context
Five patients in each group were lost to follow-up during the study period, so 49 patients in each group were analysed.
Report a problemFND-2006133403

AI wrote and checked these results. AI can make mistakes, so check important results against the source.

Registered trials1

Trials this study reports on, or that list this study as a reference. Registry data from ClinicalTrials.gov.

1 trial · source ClinicalTrials.gov (opens in a new tab)

Status unknownPhase 2NCT00993356